Table 2 Health care resource use by line of therapy and regimen in Japan, Korea, Taiwan, and Brazil
| Â | Japan | Korea | Taiwan | Brazil | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
(N = 175) | (N = 150) | (N = 217) | (N = 175) | |||||||||
Characteristic | N a | Inpatient stayb | Outpatient visit | N a | Inpatient stay | Outpatient visit | N a | Inpatient stay | Outpatient visit | N a | Inpatient stay | Outpatient visit |
First-line therapy | 134 | 109 (81) | 117 (87) | 134 | 83 (62) | 130 (97) | 172 | 94 (55) | 149 (87) | 106 | 33 (31) | 94 (89) |
 Platinum-based comb. | 94 | 84 (89) | 79 (84) | 107 | 67 (63) | 103 (96) | 33 | 26 (79) | 24 (73) | 100 | 30 (30) | 89 (89) |
 Non-platinum comb. | 0 | 0 | 0 | 0 | 0 | 0 | 26 | 17 (65) | 24 (92) | 0 | 0 | 0 |
 Single agent | 10 | 6 (60) | 9 (90) | 3 | 3 (100) | 3 (100) | 29 | 7 (24) | 28 (97) | 2 | 1 (50) | 1 (50) |
 EGFR/ALK TKI | 30 | 19 (63) | 29 (97) | 24 | 13 (54) | 24 (100) | 84 | 44 (52) | 73 (87) | 4 | 2 (50) | 4 (100) |
Second-line therapy | 89 | 75 (84) | 81 (91) | 93 | 62 (67) | 90 (97) | 131 | 70 (53) | 112 (86) | 63 | 22 (35) | 57 (90) |
 Platinum-based comb. | 22 | 17 (77) | 17 (77) | 11 | 6 (55) | 11 (100) | 35 | 25 (71) | 24 (69) | 7 | 1 (14) | 7 (100) |
 Non-platinum comb. | 2 | 2 (100) | 2 (100) | 3 | 3 (100) | 2 (67) | 30 | 10 (33) | 30 (100) | 1 | 1 (100) | 1 (100) |
 Single agent | 48 | 42 (88) | 47 (98) | 31 | 21 (68) | 31 (100) | 40 | 22 (55) | 36 (90) | 50 | 18 (36) | 44 (88) |
 EGFR/ALK TKI | 17 | 14 (82) | 15 (88) | 48 | 32 (67) | 46 (96) | 26 | 13 (50) | 22 (85) | 5 | 2 (40) | 5 (100) |